Takayasu's Arteritis
14
4
4
8
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 14 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
13%
1 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (14)
Global Initiative on Takayasu Arteritis (GITA)
Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis
One-Time DNA Study for Vasculitis
Determining Disease Activity Biomarkers in Individuals With Takayasu's Arteritis
A Registry Study on Biomarkers of Takayasu's Arteritis (ARSBTA)
VCRC Patient Contact Registry Patient-Reported Data Validation Study
Exercise in Juvenile Takayasu Disease
Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis
Clinical Study of Anti-tumor Necrosis Factor Therapy in Patients With Takayasu Arteritis
Carotid Artery Neovascularization in Takayasu's and Giant Cell Arteritis
Impact of Vasculitis on Employment and Income
Educational Needs of Patients With Systemic Vasculitis
Vasculitis Illness Perception (VIP) Study
Reproductive Health in Men and Women With Vasculitis